Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
BackgroundBevacizumab (BEV) plus chemotherapy as a neoadjuvant regimen presents good efficacy in patients with locally advanced cancer. However, its role in patients with locally advanced gastric cancer (LAGC) is not clear. Thus, the study aimed to assess the efficacy and safety of neoadjuvant BEV p...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.842828/full |
| _version_ | 1828823120234938368 |
|---|---|
| author | Deguo Yu Zhenfeng Wang Tingbang He Lijun Yang |
| author_facet | Deguo Yu Zhenfeng Wang Tingbang He Lijun Yang |
| author_sort | Deguo Yu |
| collection | DOAJ |
| description | BackgroundBevacizumab (BEV) plus chemotherapy as a neoadjuvant regimen presents good efficacy in patients with locally advanced cancer. However, its role in patients with locally advanced gastric cancer (LAGC) is not clear. Thus, the study aimed to assess the efficacy and safety of neoadjuvant BEV plus chemotherapy in patients with LAGC.MethodsTwenty resectable patients with LAGC who received BEV plus docetaxel/cisplatin/capecitabine (DCC) chemotherapy for 3 cycles with 21 days as one cycle as neoadjuvant regimen were involved. Besides, their treatment response, survival profiles, and adverse events were assessed.ResultsIn total, two (10.0%), 9 (45.0%), 8 (40.0%), and 1 (5.0%) patients achieved complete remission, partial remission, stable disease, and progressive disease (PD) according to imaging evaluation, which resulted in 55.0% of objective response rate and 95.0% of disease control rate, respectively. Moreover, the number of patients with pathological response grades 1, 2, and 3 was 8 (40.0%), 8 (40.0%), and 3 (15.0%); while 1 (5.0%) patient did not receive surgery due to PD, thus the data of this patient was not assessable. Meanwhile, 18 (90.0%) patients achieved R0 resection. Regarding survival profile, the median disease-free survival or overall survival were both not reached. The 1-year, 2-, and 3-year disease-free survival rates were 88.8, 80.7, and 67.3%. Meanwhile, the 1-, 2-, and 3-year overall survival rates were 100.0%, 75.8%, and 75.8%, respectively. Additionally, the main adverse events were anemia (90.0%), alopecia (90.0%), leukopenia (70.0%), and anorexia (65.0%). Indeed, most adverse events were of grade 1 or 2 and were manageable.ConclusionNeoadjuvant BEV plus DCC chemotherapy presents a favorable pathological response and survival profile with acceptable safety in patients with LAGC. |
| first_indexed | 2024-12-12T13:28:50Z |
| format | Article |
| id | doaj.art-a86e630f087c4c9d8268f51f4fa20418 |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-12-12T13:28:50Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-a86e630f087c4c9d8268f51f4fa204182022-12-22T00:23:07ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2022-05-01910.3389/fsurg.2022.842828842828Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot StudyDeguo Yu0Zhenfeng Wang1Tingbang He2Lijun Yang3Department of Emergency Surgery, The Second People's Hospital of Liaocheng, Linqing, ChinaDepartment of General Surgery, The Second People's Hospital of Liaocheng, Linqing, ChinaDepartment of General Surgery, The People's Hospital of XiaJin Affiliated to Shandong First Medical University, Xiajin, ChinaDepartment of Emergency, The Second People's Hospital of Liaocheng, Linqing, ChinaBackgroundBevacizumab (BEV) plus chemotherapy as a neoadjuvant regimen presents good efficacy in patients with locally advanced cancer. However, its role in patients with locally advanced gastric cancer (LAGC) is not clear. Thus, the study aimed to assess the efficacy and safety of neoadjuvant BEV plus chemotherapy in patients with LAGC.MethodsTwenty resectable patients with LAGC who received BEV plus docetaxel/cisplatin/capecitabine (DCC) chemotherapy for 3 cycles with 21 days as one cycle as neoadjuvant regimen were involved. Besides, their treatment response, survival profiles, and adverse events were assessed.ResultsIn total, two (10.0%), 9 (45.0%), 8 (40.0%), and 1 (5.0%) patients achieved complete remission, partial remission, stable disease, and progressive disease (PD) according to imaging evaluation, which resulted in 55.0% of objective response rate and 95.0% of disease control rate, respectively. Moreover, the number of patients with pathological response grades 1, 2, and 3 was 8 (40.0%), 8 (40.0%), and 3 (15.0%); while 1 (5.0%) patient did not receive surgery due to PD, thus the data of this patient was not assessable. Meanwhile, 18 (90.0%) patients achieved R0 resection. Regarding survival profile, the median disease-free survival or overall survival were both not reached. The 1-year, 2-, and 3-year disease-free survival rates were 88.8, 80.7, and 67.3%. Meanwhile, the 1-, 2-, and 3-year overall survival rates were 100.0%, 75.8%, and 75.8%, respectively. Additionally, the main adverse events were anemia (90.0%), alopecia (90.0%), leukopenia (70.0%), and anorexia (65.0%). Indeed, most adverse events were of grade 1 or 2 and were manageable.ConclusionNeoadjuvant BEV plus DCC chemotherapy presents a favorable pathological response and survival profile with acceptable safety in patients with LAGC.https://www.frontiersin.org/articles/10.3389/fsurg.2022.842828/fullBevacizumab plus chemotherapyneoadjuvant regimentreatment responsesurvival dataadverse events |
| spellingShingle | Deguo Yu Zhenfeng Wang Tingbang He Lijun Yang Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study Frontiers in Surgery Bevacizumab plus chemotherapy neoadjuvant regimen treatment response survival data adverse events |
| title | Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study |
| title_full | Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study |
| title_fullStr | Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study |
| title_full_unstemmed | Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study |
| title_short | Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study |
| title_sort | neoadjuvant bevacizumab plus docetaxel cisplatin capecitabine chemotherapy in locally advanced gastric cancer patients a pilot study |
| topic | Bevacizumab plus chemotherapy neoadjuvant regimen treatment response survival data adverse events |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2022.842828/full |
| work_keys_str_mv | AT deguoyu neoadjuvantbevacizumabplusdocetaxelcisplatincapecitabinechemotherapyinlocallyadvancedgastriccancerpatientsapilotstudy AT zhenfengwang neoadjuvantbevacizumabplusdocetaxelcisplatincapecitabinechemotherapyinlocallyadvancedgastriccancerpatientsapilotstudy AT tingbanghe neoadjuvantbevacizumabplusdocetaxelcisplatincapecitabinechemotherapyinlocallyadvancedgastriccancerpatientsapilotstudy AT lijunyang neoadjuvantbevacizumabplusdocetaxelcisplatincapecitabinechemotherapyinlocallyadvancedgastriccancerpatientsapilotstudy |